Efficacy and safety of omalizumab in Japanese and Korean patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): Results from the phase III POLARIS study

被引：0
|
作者：
Hide, Michihiro
Park, Hae-Sim [1 ]
Igarashi, Atsuyuki [2 ]
Ye, Young Min [1 ]
Kim, Tae-Bum [3 ]
Yagami, Akiko [4 ]
Lee, Jae-Hyun
Fukunaga, Atsushi [5 ]
Khalil, Sam [6 ]
机构：
[1] Ajou Univ, Sch Med, Suwon, South Korea
[2] NTT Med Ctr Tokyo, Tokyo, Japan
[3] Asan Med Ctr, Seoul, South Korea
[4] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan
[5] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan
[6] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
4820
引用
收藏
页码：AB112 / AB112
页数：1
相关论文
共 50 条
  • [1] Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
    Yan, Che-Wen
    Cho, Yung-Tsu
    Chu, Chia-Yu
    DERMATOLOGICA SINICA, 2017, 35 (04) : 182 - 186
  • [2] Efficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
    Casale, Thomas
    Maurer, Marcus
    Hsieh, Hsin-Ju
    Canvin, Janice
    Saini, Sarbjit S.
    Grattan, Clive
    Gimenez-Arnau, Ana
    Kaplan, Allen P.
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB327 - AB327
  • [3] Clinical Characteristics of Adolescent Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) in Three Phase III Studies with Omalizumab
    Goldstein, Stanley
    Skoner, David P.
    Ortiz, Benjamin
    Kianifard, Farid
    Vu, Julie
    Mendelson, Meryl
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB129 - AB129
  • [4] Omalizumab effectively reduces angioedema episodes in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU)
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Canvin, J.
    Maurer, M.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 18 - 18
  • [5] Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria
    Michihiro, Hide
    Hae-Sim, Park
    Atsuyuki, Igarashi
    Young-Min, Ye
    Tae-Bum, Kim
    Akiko, Yagami
    Jooyoung, Roh
    Jae-Hyun, Lee
    Yuko, Chinuki
    Woong, Youn Sang
    Soo-Keol, Lee
    Naoko, Inomata
    Jeong-Hee, Choi
    Atsushi, Fukunaga
    Junyi, Wang
    Soichiro, Matsushima
    Steve, Greenberg
    Sam, Khalil
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 87 (01) : 70 - 78
  • [6] Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
    Hide, Michihiro
    Igarashi, Atsuyuki
    Yagami, Akiko
    Chinuki, Yuko
    Inomata, Naoko
    Fukunaga, Atsushi
    Kaiser, Guenther
    Wang, Junyi
    Matsushima, Soichiro
    Greenberg, Steven
    Khalil, Sam
    ALLERGOLOGY INTERNATIONAL, 2018, 67 (02) : 243 - 252
  • [7] Clinical profile of patients with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) in phase III omalizumab studies: Analyses according to the presence or absence of angioedema
    Sofen, Howard
    Mendelson, Meryl
    Vu, Julie
    Kianifard, Farid
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB43 - AB43
  • [8] Baseline Characteristics of Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Enrolled in a Phase III, Randomized, Placebo-Controlled Trial of Omalizumab
    Rosen, Karin
    Hsieh, Hsin-Ju
    Georgiou, Panayiotis
    Casale, Thomas
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB29 - AB29
  • [9] REAL-WORLD TREATMENT PATTERNS OF OMALIZUMAB IN CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA (CIU/CSU) PATIENTS IN THE UNITED STATES
    Eghrari-Sabet, J.
    Sher, E.
    Lefebvre, P.
    Pilon, D.
    Zhdanava, M.
    Balp, M.
    Kavati, A.
    Ortiz, B.
    Bernstein, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S42 - S42
  • [10] Design and rationale of the optima study: retreatment or step-up therapy with omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU)
    Sussman, G.
    Hebert, J.
    Gulliver, W.
    Lynde, C. W.
    Yang, W. H.
    Deutsch, G.
    Chambenoit, O.
    Detakascy, F.
    Rihakova, L.
    ALLERGY, 2017, 72 : 713 - 713
12345